PRKCD and glycogen storage disease VI: A TAT-fusion peptide inhibitor of protein kinase C delta(KAI-9803) showed promise in a clinical trial of myocardial infarct size reduction[38].Additional clinical trials are underway for treatment of ischemic stroke andneurodegenerative disease using KAI-9803 [39].